Surrey researchers Sign in
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours
Journal article

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

L Horsley, J Cummings, M Middleton, T Ward, A Backen, A Clamp, M Dawson, H Farmer, N Fisher, G Halbert, …
CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.72(6), pp.1343-1352
01/12/2013

Abstract

Science & Technology Life Sciences & Biomedicine Oncology Pharmacology & Pharmacy ONCOLOGY PHARMACOLOGY & PHARMACY Phase 1 GSAO Novel arsenic compound Clinical trial DCE-MRI ACUTE PROMYELOCYTIC LEUKEMIA APOPTOSIS PROTEIN XIAP X-LINKED INHIBITOR ARSENIC TRIOXIDE CLINICAL-EFFICACY ANGIOGENESIS INHIBITOR METABOLISM INHIBITORS CANCER-THERAPY CELL-DEATH VALIDATION
url
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000327387000020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11d2a86992e85fb529977dad66a846d5View
Author

Metrics

Details

Usage Policy